Homepage Top Section2

Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014.

The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is designed for

The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a second-generation, Fc-enhanced

RXRG001 is a circular ribonucleic acid (RNA) therapy encoding human aquaporin-1, a protein involved in fluid transport. The therapy is encapsulated within lipid nanoparticles and directly administered to

The purchase adds an established hypertension brand to Novartis’ cardiovascular range. Novartis India’s board cleared the deal, after which the company signed an asset purchase agreement and trademark

This combo is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance applies when an estrogen receptor 1 (ESR1) mutation is

The funding was led by BVF Partners, with participation from new investors Deep Track Capital and Perceptive Advisors. Existing backers included Catalio Capital Management, Cooley, Eli Lilly and

The contract allows Qilu Pharmaceutical to use the antibody, which was developed through Biocytogen’s RenNano platform, in its research and development (R&D) activities focused on neuroscience therapeutics. It

The agreement will see Aitia apply its REFS technology to build Gemini Digital Twins (GDTs) of neurological conditions to identify potential new therapeutic targets and biomarkers. Ono Pharmaceutical